Please assess the completion status of the following clinical trial:

Trial Title: MENDS Study: Trial in Ventilated ICU Patients Comparing an Alpha2 Agonist Versus a Gamma Aminobutyric Acid (GABA)-Agonist to Determine Delirium Rates, Efficacy of Sedation, Analgesia and Discharge Cognitive Status

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adult patients admitted to the medical and surgical ICU for critical illnesses requiring mechanical ventilation with expectation of being mechanically ventilated for greater than 24 hours~Exclusion Criteria:~* Subjects who are less than 18 years of age~* Subjects who are pregnant (a pregnancy test will be performed on all women of child bearing age)~* Inability to obtain informed consent from the patient or his/her surrogate~* Subjects in the ICU due to a lack of beds elsewhere in the hospital, triage issues, or withdrawal of care decisions rather than severity of illness~* Subjects admitted with alcohol or drug overdoses, suicide attempts, or alcohol/delirium tremens~* Subjects who are physiologically benzodiazepine dependent, and at risk for withdrawal syndromes~* Subjects with chronic pain syndromes on maintenance narcotics~* Subjects treated within the last 30 days with a drug or device that has not received regulatory approval as of study entry~* Subjects with a psychiatric history for which they are on neuroleptic treatment~* Subjects with documented moderate to severe dementia~* Subjects with anoxic brain injuries, strokes, neurotrauma, or neuromuscular disorders such as myasthenia gravis or Guillain Barre syndrome~* Medical team following patient unwilling to use the sedation regimens~* Subjects whose family and/or physician have not committed to aggressive support for 72 hours or who are likely to withdraw within 72 hours~* Subjects who are moribund and not expected to survive 24 hours~* Subjects not expected to survive hospital discharge due to preexisting uncorrectable medical condition~* Documented allergy to study medications~* Subjects who have either Child-Pugh Class B or C cirrhosis~* Subjects with active coronary artery disease at time of screening as defined by any recent evidence of ischemia, documented myocardial infarction, or coronary intervention within the past 6 months.~* Subjects with advanced heart block at time of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: ACTIVE_COMPARATOR): Patients in the dexmedetomidine arm will receive a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. The patient's managing physician will have the option of beginning the dexmedetomidine infusion without a bolus in circumstances where the patient's sedation level is adequate at enrollment or in the presence of baseline bradycardia /hypotension. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
- Lorazepam group (Type: ACTIVE_COMPARATOR): Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).